A concise prognostic score system for diffuse large B-cell lymphoma: a retrospective study with long-term follow-up
Ying Yang1, Zhuogang Liu1, Guojun Zhang1
1Department of Hematology, Shengjing Hospital of China Medical University, Shenyang, China.
Future Oncology (London, England)
|August 5, 2021
Summary
Identifying risk factors for diffuse large B-cell lymphoma (DLBCL) is crucial. A new scoring system found old age, low BMI, high CA125, and no rituximab application predict poor outcomes in DLBCL patients.
Area of Science:
- Hematology
- Oncology
- Clinical Research
Background:
- Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma.
- Accurate prognostic tools are essential for guiding treatment decisions in DLBCL patients.
Purpose of the Study:
- To identify independent risk factors associated with outcomes in DLBCL.
- To develop and validate a concise prognostic scoring system for DLBCL patients.
Main Methods:
- Retrospective analysis of 131 DLBCL patients with long-term follow-up.
- Multivariate analysis to determine independent risk factors.
- Development and validation of a prognostic scoring system.
Main Results:
- Independent risk factors identified: older age, lower body mass index (BMI), elevated CA125 levels, and absence of rituximab treatment.
- The developed prognostic score effectively stratified patients into low-, medium-, and high-risk groups.
- Significant differences in overall survival (OS) and progression-free survival (PFS) were observed among the risk groups (p < 0.05).
Conclusions:
- Old age, low BMI, high CA125, and lack of rituximab are significant independent risk factors for DLBCL.
- The novel prognostic scoring system accurately identifies high-risk DLBCL patients.
- This scoring system can aid in risk stratification and personalized treatment strategies for DLBCL.
